Diclofenac derivatives as promising anticancer and anti-inflammatory drug: Synthesis, formulations, and pharmacokinetics

被引:3
作者
Alshargabi, Arwa [1 ,2 ]
机构
[1] Saba Univ, Fac Med Sci, Pharm Dept, Sanaa, Yemen
[2] Al Nasser Univ, Fac Med & Hlth Sci, Dept Pharm, Sanaa, Yemen
关键词
Diclofenac; Nanoparticle; Anti-inflammatory; Drug release; Anticancer; IN-VITRO CHARACTERIZATION; PHARMACOLOGICAL EVALUATION; METABOLIC-ACTIVATION; MOLECULAR-MECHANISMS; TRANSDERMAL DELIVERY; ACYL GLUCURONIDE; SKIN PERMEATION; VIVO EVALUATION; ELLAGIC ACID; SODIUM;
D O I
10.1016/j.jddst.2024.105544
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diclofenac (DCF) is well-known non-steroidal anti-inflammatory drug used in the treatment of several cancer cell lines. DCF is derived from phenylacetic acid, and its pharmaceutical activity is attributed to the carboxylic acid moiety. The carboxylic acid group is also responsible for the DCF's side effects, which include gastrointestinal bleeding and ulceration. Therefore, researchers do vast efforts and proposed many strategies to reduce DCF hepatotoxicity. In this regard, the present review provides a comparison and insight into recent developments in DCF through structural modification, drug delivery carriers (multiparticles, microparticles, and nanoparticles), and pharmacokinetics to reduce the toxicity side effects while simultaneously enhancing sustained drug release and the pharmaceutical effect. The researchers demonstrated that the nature and quantity of polymeric drug vehicles (hydrophilic or hydrophobic polymers) have a profound effect on DCF release rate, encapsulation efficiency, and mechanism of action. Furthermore, masking the DCF carboxylic acid with certain moieties such as hydrazones or heterocyclics could substantially boost the pharmaceutical and anticancer activities with a significant reduction in ulcerogenic effect. In this review, comparisons between the published DCF prodrugs, commercial formulations, and parent drug DCF based on the pharmacokinetics (the area under the concentration-time curve from dosing time 0 to infinity, time to reach the maximum concentration, and concentration of the agent inhibiting cell growth by 50%) were also elucidated. It also briefly summarizes the synergistic interactions between DCF with some bio-enhancers. In the last section, we highlighted how the researchers incorporated artificial intelligence during the drug formulation to overcome hepatotoxicity and used it to predict its activity against cancer cell lines. In the last line, this review will serve as compilation of useful and recent sources, which are indexed in Scopus, PubMed, Academic Search Complete, and others, on how scientists created more efficient and sustained release DCF formulations, and how they made it safer with almost no side effects.
引用
收藏
页数:23
相关论文
共 146 条
  • [71] Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents
    Kryshchyshyn, Anna
    Kaminskyy, Danylo
    Karpenko, Oleksandr
    Gzella, Andrzej
    Grellier, Philippe
    Lesyk, Roman
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 174 : 292 - 308
  • [72] Therapeutic potential of Aloe vera-A miracle gift of nature
    Kumar, Ramesh
    Singh, Amit Kumar
    Gupta, Ashutosh
    Bishayee, Anupam
    Pandey, Abhay K.
    [J]. PHYTOMEDICINE, 2019, 60
  • [73] Pharmacokinetic and pharmacodynamic studies on interaction of "Trikatu" with diclofenac sodium
    Lala, LG
    D'Mello, PM
    Naik, SR
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2004, 91 (2-3) : 277 - 280
  • [74] Artificial neural network for modeling formulation and drug permeation of topical patches containing diclofenac sodium
    Lefnaoui, Sonia
    Rebouh, Samia
    Bouhedda, Mounir
    Yahoum, M. Madiha
    [J]. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2020, 10 (01) : 168 - 184
  • [75] Incorporating active pharmaceutical ingredients into a molecular salt using a chiral counterion
    Lemmerer, Andreas
    Bourne, Susan A.
    Caira, Mino R.
    Cotton, Jonathan
    Hendricks, Umraan
    Peinke, Laura C.
    Trollope, Lee
    [J]. CRYSTENGCOMM, 2010, 12 (11): : 3634 - 3641
  • [76] Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery
    Lengyel, Milena
    Kallai-Szabo, Nikolett
    Antal, Vince
    Laki, Andras Jozsef
    Antal, Istvan
    [J]. SCIENTIA PHARMACEUTICA, 2019, 87 (03)
  • [77] NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS) ASSOCIATE WITH ZWITTERIONIC PHOSPHOLIPIDS - INSIGHT INTO THE MECHANISM AND REVERSAL OF NSAID-INDUCED GASTROINTESTINAL INJURY
    LICHTENBERGER, LM
    WANG, ZM
    ROMERO, JJ
    ULLOA, C
    PEREZ, JC
    GIRAUD, MN
    BARRETO, JC
    [J]. NATURE MEDICINE, 1995, 1 (02) : 154 - 158
  • [78] Lin SY, 2000, J MICROENCAPSUL, V17, P577
  • [79] Conductomeric Evaluation of the Release Kinetics of Active Substances from Pharmaceutical Preparations Containing Iron Ions
    Lisik, Anna
    Musial, Witold
    [J]. MATERIALS, 2019, 12 (05):
  • [80] Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method
    Liu, Dongfei
    Jiang, Sunmin
    Shen, Hong
    Qin, Shan
    Liu, Juanjuan
    Zhang, Qing
    Li, Rui
    Xu, Qunwei
    [J]. JOURNAL OF NANOPARTICLE RESEARCH, 2011, 13 (06) : 2375 - 2386